Your browser doesn't support javascript.
loading
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello, Alex; Herranz, Jose Maria; Latasa, Maria Ujue; Arechederra, Maria; Uriarte, Iker; Pineda-Lucena, Antonio; Prosper, Felipe; Berraondo, Pedro; Alonso, Cristina; Sangro, Bruno; García Marin, Jose Juan; Martinez-Chantar, Maria Luz; Ciordia, Sergio; Corrales, Fernando José; Francalanci, Paola; Alaggio, Rita; Zucman-Rossi, Jessica; Indersie, Emilie; Cairo, Stefano; Domingo-Sàbat, Montserrat; Zanatto, Laura; Sancho-Bru, Pau; Armengol, Carolina; Berasain, Carmen; Fernandez-Barrena, Maite García; Avila, Matias Antonio.
Afiliação
  • Clavería-Cabello A; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
  • Herranz JM; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
  • Latasa MU; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
  • Arechederra M; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
  • Uriarte I; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain.
  • Pineda-Lucena A; Molecular Therapeutics Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
  • Prosper F; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain; Oncohematology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
  • Berraondo P; Immunology and Immunotherapy Program, CIMA, University of Navarra, Pamplona, Spain; CIBERonc, Madrid, Spain.
  • Alonso C; OWL Metabolomics, Derio, Spain.
  • Sangro B; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain; Hepatology Unit, CCUN, Navarra University Clinic, Pamplona, Spain.
  • García Marin JJ; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Experimental Hepatology and Drug Targeting (HEVEFARM), University of Salamanca, IBSAL, Salamanca, Spain.
  • Martinez-Chantar ML; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CICbioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.
  • Ciordia S; Functional Proteomics Laboratory, CNB-CSIC, Madrid, Spain.
  • Corrales FJ; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Functional Proteomics Laboratory, CNB-CSIC, Madrid, Spain.
  • Francalanci P; Pathology Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy.
  • Alaggio R; Pathology Unit, Children's Hospital Bambino Gesù, IRCCS, Sapienza University, Rome, Italy.
  • Zucman-Rossi J; Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, INSERM, Hôpital Européen Georges Pompidou, Paris, France.
  • Indersie E; XenTech, Evry-Courcouronnes, France.
  • Cairo S; XenTech, Evry-Courcouronnes, France; Champions Oncology, Rockville, MD, USA.
  • Domingo-Sàbat M; Childhood Liver Oncology Group, Program of Predictive and Personalized Medicine of Cancer (PMPCC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Zanatto L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Sancho-Bru P; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Armengol C; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Childhood Liver Oncology Group, Program of Predictive and Personalized Medicine of Cancer (PMPCC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain.
  • Berasain C; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain.
  • Fernandez-Barrena MG; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain. Electronic address: magarfer@unav.es.
  • Avila MA; Hepatology Program, CIMA, CCUN, University of Navarra, Pamplona, Spain; CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Pamplona, Spain. Electronic address: maavila@unav.es.
J Hepatol ; 79(4): 989-1005, 2023 10.
Article em En | MEDLINE | ID: mdl-37302584
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatoblastoma / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatoblastoma / Neoplasias Hepáticas Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Hepatol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha